"MIATA"-minimal information about T cell assays.
Data(s) |
2009
|
---|---|
Resumo |
Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem. |
Identificador |
https://serval.unil.ch/notice/serval:BIB_07A00768009A info:pmid:19833080 https://serval.unil.ch/resource/serval:BIB_07A00768009A.P001/REF http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_07A00768009A7 urn:nbn:ch:serval-BIB_07A00768009A7 |
Idioma(s) |
eng |
Fonte |
Immunity314527-528 |
Palavras-Chave | #Cancer Vaccines/immunology; Cancer Vaccines/therapeutic use; Humans; Immunoassay/standards; Immunotherapy; Monitoring, Immunologic/standards; Neoplasms/therapy; Practice Guidelines as Topic/standards; T-Lymphocytes/immunology; Viral Vaccines/immunology; Viral Vaccines/therapeutic use; Virus Diseases/therapy |
Tipo |
info:eu-repo/semantics/article article |
Formato |
application/pdf |
Direitos |
info:eu-repo/semantics/openAccess Copying allowed only for non-profit organizations https://serval.unil.ch/disclaimer |